



**HAL**  
open science

## Steroid-Fullerene hybrids: A review

Malika Ibrahim-Ouali, Frédéric Dumur

► **To cite this version:**

Malika Ibrahim-Ouali, Frédéric Dumur. Steroid-Fullerene hybrids: A review. ARKIVOC - Online Journal of Organic Chemistry, 2022, 2022 (1), 10.24820/ark.5550190.p011.734 . hal-03648063

**HAL Id: hal-03648063**

**<https://hal.science/hal-03648063>**

Submitted on 21 Apr 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

## Steroid-Fullerene hybrids: A review

Malika Ibrahim-Ouali,<sup>\*a</sup> and Frédéric Dumur<sup>b</sup>

<sup>a</sup>Aix Marseille Univ, CNRS, Centrale Marseille, iSm2, F-13397 Marseille, France

<sup>b</sup>Aix Marseille Univ, CNRS, ICR, UMR 7273, F-13397 Marseille, France

Email address: malika.ibrahim@univ-amu.fr


Received mm-dd-yyyy

Accepted mm-dd-yyyy

Published on line mm-dd-yyyy

### Abstract

Among carbon-based materials, fullerenes have emerged as very fascinating nanocarbons on account of the interesting properties and applications of some of their derivatives in medicine or materials chemistry. The low solubility of C<sub>60</sub>, the most famous family member, has limited its use in medicinal chemistry but its covalent functionalization with different moieties such as porphyrins or other bioactive molecules changes its physicochemical properties, such as its solubility and biocompatibility. New hybrid compounds, bearing fullerene and steroid units in the same molecule can be regarded as promising functional chimeras with encouraging biomedical applications and have become a topic of considerable interest in the last few years. Recent developments in the syntheses of steroid-fullerene hybrids are described herein.



**Keywords:** steroid; C<sub>60</sub>-fullerene; hybrid molecules; linkage.

## Table of Contents

1. Introduction
2. Synthesis of steroid- fullerene hybrids
3. Conclusions
4. Acknowledgments
5. References

## 1. Introduction

Steroids constitute an extensive and important class of biologically active polycyclic compounds that are widely used for therapeutic purposes.<sup>1-3</sup> Even after decades of research, the total synthesis of steroid nuclei by improved strategies continues to receive considerable attention. Numerous methods<sup>4,5</sup> have been exploited for the total synthesis of steroids which are widely distributed in nature, and which possess practical medical importance. Research into steroid total synthesis continues to this day.

The C<sub>60</sub> fullerene is the most common fullerene. Since its discovery, it is at the origin of many studies in various fields.<sup>6</sup> Indeed, the family of fullerenes and especially its main representative, C<sub>60</sub>, has exceptional physicochemical properties at the origin of their interest. These compounds have unique optical,<sup>7-9</sup> electrophysical,<sup>10-12</sup> mechanical,<sup>13-15</sup> tribological,<sup>16-18</sup> sorption<sup>19-22</sup> and biological<sup>23-25</sup> properties. New dyes and catalysts<sup>26-30</sup> have even been discovered among functionalized fullerenes. The use of functionalized fullerenes in the field of medical chemistry, in particular for the treatment of significant diseases, seems interesting because of their wide range of biological activity.

In recent years, hybrid systems have grown in importance due to their many applications in medicine and drug development. Hybrid systems are formed from different molecular entities, natural or not, to obtain functional molecules in which the characteristics of various moieties are amplified or modulated or lead to completely new properties. These hybrids can be made from carefully selected components, either through direct covalent bonds or through the integration of key functional characteristics.

These promising molecules make it possible to generate new molecular entities by intelligently combining two or more different classes of compounds of synthetic or natural origin. The interest is to be able to mix the structural characteristics of two or more biologically active molecules in the same molecule or their covalent coupling can improve the characteristics of the individual components or reveal new properties. In all cases, this approach is interesting because it offers a multitude of possibilities for generating a wide range of molecules for applications in biology, medicine and in the field of materials.


This article provides an overview of the various syntheses of steroid-fullerene hybrids along with interesting biological activities. To the best of our knowledge and much to our surprise, there are no reports on this subject.

## 2. Synthesis of steroid-fullerene hybrids

One of the main drawbacks to the potential use of C<sub>60</sub> in medical applications is its lack of solubility in water and its very poor solubility in most conventional organic solvents.<sup>31-32</sup> Covalent binding of [60]fullerene to


suitably functionalized molecules is an effective approach to overcome this problem of solubility. Thus, steroids which are bioactive molecules have been covalently connected to C<sub>60</sub> fullerene by various authors.

Two main reactions were used to synthesize these systems: nucleophilic cyclopropanation using the Bingel protocol and thermal addition of steroidal compounds. The Bingel reaction is a fullerene cyclopropanation reaction to a methanofullerene, first discovered by C. Bingel<sup>33</sup> with the bromo derivative of diethyl malonate in the presence of a base such as sodium hydride or DBU (Scheme 1).




**Scheme 1.** The Bingel reaction.

In 1999, Schuster and coworkers<sup>34</sup> reported the synthesis of steroid-fullerene hybrids using the Prato reaction.<sup>35</sup> The Prato reaction is a particular example of the well-known 1,3-dipolar cycloaddition of azomethine ylides to olefins. The amino acid *N*-methylglycine reacts with paraformaldehyde when heated at reflux in toluene to provide an ylide which reacts with a double bond in a 6,6-ring position of the fullerene *via* a 1,3-dipolar cycloaddition to yield a pyrrolidinofullerene (Scheme 2).






**Scheme 2.** The Prato reaction.

Here, the Prato reaction<sup>35</sup> was used to synthesize the steroidal fulleropyrrolidine precursors **1**, **2**, and **3** (Figure 1).



**Figure 1.** Synthesis of steroidal fulleropyrrolidine precursors **1**, **2**, and **3** and the tetraphenylporphyrin carboxylic acid **4**.

Union of these precursors with tetraphenylporphyrin carboxylic acid **4** was realized through a standard EDCI coupling to furnish the fullerene-steroid hybrids **5-7** (Figure 2).




**Figure 2.** Synthesis of steroid-fullerene hybrids **5**, **6**, and **7**.

In 2001, Yang et al.<sup>36</sup> described the synthesis of two new steroid-fullerene hybrids by a Diels–Alder reaction as the key step.

The synthetic pathway is depicted in Scheme 3. Treatment of the available steroid 3'-acetoxypregna-5,16-dien-20-one **8** with LiOH led to **9** in 90% yield. This latter was easily transformed by reaction with *tert*-butyldimethylsilyl triflate into the desired silyoxydiene **10** in an isolated yield of 85%. Reaction of C<sub>60</sub> with **10** in toluene at 90 °C for 2 h led to the desired molecule **12** in a yield of 30% (in two steps, 40% yield based on C<sub>60</sub> consumed) after hydrolysis of the enol silyl ether and deprotection of the hydroxy group at C-3 using classic acid conditions.

A biological study on the cytotoxic effects of hybrid **12** has been carried out at the cellular level. The authors observed its effect on the transmembrane membrane of the reconstituted sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase (SR Ca<sup>2+</sup>-ATPase) in soybean phospholipid liposomes. Thus, they were able to conclude that compound **12** can inhibit the enzyme. In addition, they also observed its effect on the survival of human lung adenocarcinoma A549 cells. The authors find that the survival of A549 cells after treatment with the steroid-C<sub>60</sub> **12** is reduced. Eukaryotic cells are rich in membrane structures. Steroid-fullerene hybrids could be the cause and lead to abnormal cell functions and therefore decrease the survival of A549 cells.




Reagents : a-THF/H<sub>2</sub>O, LiOH, 90%; b- TBSOTf, NEt<sub>3</sub>, 85%;  
c- C<sub>60</sub>, toluene, Δ; d- *p*TsOH, Δ, 40% (two steps).

### Scheme 3. Synthesis of steroid-fullerene hybrid **12**.

In 2009, Martin et al.<sup>37</sup> reported the synthesis of a new series of hybrid functionalized chimeras **17-18** (Scheme 4) and **21** (Scheme 5) by cyclopropanations between C<sub>60</sub> and readily available malonates bearing different steroid moieties **15-16**, and **20** using the Bingel–Hirsch protocol.

The synthesis of these hybrid molecules is shown in Schemes 4 and 5. The malonates **15**, **16** and **20** necessaries for the synthesis of these hybrid systems were prepared by treating three different sterols - cholesterol **13**, β-sitosterol **14**, and ergosterol **19** - with acetyl chloride (ethoxycarbonyl) commercially available. The reactions, carried out in anhydrous dichloromethane and pyridine at 0 °C, gave the desired

malonates **15**, **16** (Scheme 4), and **20** (Scheme 5) with respective yields of 85%, 74% and 70%. Cyclopropanation under Bingel-Hirsch conditions, by treatment of **15**, **16**, or **20** with C<sub>60</sub> in the presence of CBr<sub>4</sub> and DBU allowed the covalent binding of malonates **15-16**, and **20** previously synthesized with C<sub>60</sub> fullerene. The expected hybrid systems **17**, **18**, and **21** were obtained very quickly (2 h) with moderate yields (50 to 58%) as stable brown solids.



Reagents : a- CH<sub>2</sub>Cl<sub>2</sub>, pyridine, 0°C, 24 h; b- C<sub>60</sub>, DBU/CBr<sub>4</sub>, toluene, r.t.

#### Scheme 4. Synthesis of steroid-fullerene hybrids **17** and **18**.


The authors were able to observe the formation of product **21** containing two additional oxygen atoms resulting from the Bingel-Hirsch reaction between compound **20** and C<sub>60</sub> (see scheme 5). Another Diels-Alder cycloaddition reaction with <sup>1</sup>O<sub>2</sub>, like that observed for ergosterol itself,<sup>38</sup> takes place at the 5,6-diene moiety of ring B. It is interesting to note that this cycloaddition is observed only when the diene system is in an environment containing oxygen and an effective triplet sensitizer, such as C<sub>60</sub>. Thus, molecular oxygen, generally in a triplet ground state, is excited in a singlet state and reacts as a dienophile with the diene unit of the steroid leading to an endoperoxide following a Diels-Alder cycloaddition reaction.

The proposed structures are confirmed by their electronic spectra as well as by cyclic voltammetry, which allows concluding to the formation only of mono adducts, without observation of any formation of bis-



cycloadducts which would come from the intramolecular Diels-Alder cycloaddition of the steroid diene part of ergosterol at C-7 to the fullerene double bond.

These new hybrid derivatives **17**, **18**, and **21**, consisting of both fullerene and steroid units, can be considered as promising functional systems. The potential biomedical applications of these hybrid molecules have not been reported to date.



Reagents : a- CH<sub>2</sub>Cl<sub>2</sub>, pyridine, 0°C, 24 h; b- C<sub>60</sub> / O<sub>2</sub>, DBU/CBr<sub>4</sub>, toluene, r.t.

### Scheme 5. Synthesis of steroid-fullerene hybrid **21**.

In 2013, the same authors<sup>39</sup> used epiandrosterone which is an important steroid to synthesize steroid-fullerene hybrids. Indeed, this hormone is the natural metabolite of dehydroepiandrosterone *via* the enzyme 5 $\alpha$ -reductase and is known for its low androgenic activity. In addition, it is present in most mammals, including pigs.<sup>40</sup>

Prato's method was here used to synthesize potentially biologically active fullerene-steroid hybrids from formyl-substituted steroid derivatives. The fullerene-steroid conjugates **27-30** were prepared in a multistep synthetic procedure in which the C<sub>60</sub> unit has been connected to the steroid unit by Prato reaction from pristine [60]fullerene and the respective formyl-containing steroids. Thus, the first step required the preparation of formyl derivatives **25** and **26** as depicted in Scheme 6. The convenient transformation of the hydroxyl group at C-3 of the epiandrosterone **22** by oxidation gave the corresponding 5 $\alpha$ -androstane-3,17-dione **23**, whereas acetylation of **22** afforded 3 $\beta$ -acetoxy-5 $\alpha$ -androstane-17-one **24**, both in yields like those previously reported. The corresponding formyl derivatives, 3-chloro-2-formyl-17-oxo-5 $\alpha$ -androstane-2-ene **25** and 3 $\beta$ -acetoxy-17-chloro-16-formyl-5 $\alpha$ -androstane-16-ene **26**, were obtained respectively by a Vilsmeier-


Haack reaction of **23** and **24** with phosphorus oxychloride and dimethylformamide in dichloromethane. The yields obtained are good (78% and 50%, respectively) and the products crystallize after basic hydrolysis with aqueous sodium acetate.

Finally, 1,3-dipolar cycloaddition reactions of azomethine ylides generated *in situ* with C<sub>60</sub> according to the Prato protocol leads to the production of *N*-methyl-2-substituted pyrrolidino [3,4: 1,2] [60] fullerenes. Thus, the reaction is carried out by mixing the chloroformyl derivative (**25** or **26**), C<sub>60</sub> and sarcosine (*N*-methylglycine), the whole brought to reflux in toluene under an argon atmosphere for 6 h (see Scheme 6). The formation of the products is confirmed by the color change of the solution from purple to brown.

Flash chromatography makes it possible to easily separate the diastereoisomers and to obtain compounds **27**, **28**, **29** and **30**, in the form of stable brown solids, with respective yields of 42%, 31%, 28% and 47%. The stereoselectivity, which provides diastereomers **27** and **30** as main products, is relatively modest. This result agrees with the fact that the electrophile, the C<sub>60</sub> attacks preferentially on the *Re* face of the 1,3-dipole.

The absolute configuration of fulleropyrrolidines was easily determined using chiroptic properties with Cotton-typical effects in CD spectra of chiral adducts. Thus, the absolute C2 configuration for compounds **27-30** was determined to be: (*2R*) for **27**, (*2S*) for **28**, (*2S*) for **29** and (*2R*) for **30**.

Finally, the authors observed that the conjugation of epiandrosterone derivatives with C<sub>60</sub> increases the solubility of these new hybrid systems (**27-30**) in organic solvents such as chloroform, dichloromethane and dimethylformamide, among others. It is therefore undeniable that the presence of the steroid unit in the new hybrid compounds (**27**, **28**, **29** and **30**) improves their solubility. This result allowed the authors to consider other investigations on these structures, especially biological ones.



Reagents : a- acetone, Jones' reagent, r.t.; b- acetic anhydride, pyridine, r.t.;  
 c- POCl<sub>3</sub>, DMF, reflux; d- C<sub>60</sub>, N-methylglycine, toluene, reflux.

### Scheme 6. Synthesis of steroid-fullerene hybrids **27-30**.

In 2014, the same authors<sup>41</sup> described the multistep synthesis of a fullerene hybrid dumbbell having two fullerene units connected through an epiandrosterone molecule.


Thanks to the presence of a formyl group at the C-16 position of ring D of the starting product **26**, the first C<sub>60</sub> unit was introduced by a 1,3-dipolar cycloaddition reaction. And after the transformation of the acetate group

attached to position C-3 in ring A into the corresponding malonate, a cyclopropanation reaction made it possible to introduce the second unit of C<sub>60</sub> (see Scheme 7).

After hydrolysis with potassium carbonate in methanol of the acetate group in C-3 position of the 3 $\beta$ -acetoxy-17-chloro-16-formyl-5 $\alpha$ -androstan-16-ene **26**, the 17-chloro-16-formyl-3 $\beta$ -hydroxy-5 $\alpha$ -androstan-16-ene **31** was isolated in good yield (92%) and allowed the incorporation of the malonate moiety by reaction of **31** with (ethoxycarbonyl)acetyl chloride in anhydrous dichloromethane and pyridine at 0 °C. This latter bearing a formyl group was obtained as a pale-yellow solid in 82% yield. The 1,3-dipolar cycloaddition of **32** was done by reaction with [60]fullerene and *N*-methylglycine in refluxing toluene leading to *N*-methyl-2-(3' $\beta$ -ethylmalonate-17'-chloro-5' $\alpha$ -androstan-16'-ene)pyrrolidine-[3,4:1,2][60]fullerenes **33** and **34**. These molecules present a new stereocenter at C-2 in the pyrrolidine ring, and therefore, two diastereomers are formed. These stereoisomers **33** and **34** were easily separated by flash chromatography leading to stable amorphous brown solids **33** and **34** with moderate yields (**34**, 34%; **35**, 27%).

The fullerene dumbbell derivative **35** was obtained by reaction of diastereomer **34** bearing a malonate moiety to [60]fullerene under Bingel–Hirsch conditions. Treatment of **34** with C<sub>60</sub> in the presence of CBr<sub>4</sub> and DBU led after 4 h, to the formation of the dumbbell derivative **35**. The pure fullerene dimer **35** was isolated after purification by flash chromatography as a stable brown solid in 55% yield (see Scheme 7).

The new compounds **33–35** have been characterized by spectroscopy and their redox potentials, determined by cyclic voltammetry, reveal three reversible reduction waves for hybrids **33** and **34**, whereas these signals are split in dumbbell **35**. The most stable conformations for the hybrid compounds (**33–35**) were determined by theoretical calculations at semiempirical (AM1) and single point B3LYP/6-31G(d) levels, and show the importance of the chlorine atom on the D ring of the steroid. Indeed, it seems to be clear that the existence of a hydrogen bond C–H...Cl contributes to the stabilization of the hybrid systems.



Reagents : a-  $K_2CO_3$  (5%), MeOH, r.t.; b- (ethoxycarbonyl)acetyl chloride, DCM, pyridine, 0 °C;  
 c-  $C_{60}$ , *N*-methylglycine, toluene, reflux; d-  $C_{60}$ ,  $CBR_4$ , DBU, toluene, r.t.

### Scheme 7. Synthesis of steroid-fullerene hybrids 33-35.


The same year, Bjelakovic et al.<sup>42</sup> reported the synthesis, morphological study, and preliminary *in vitro* antioxidant capacity of new fullerene-steroid hybrids.

The synthetic strategy to obtain the fullerene-peptide-steroid hybrids **40** and **42** are depicted in Schemes 8 and 9 and show firstly the synthesis of a steroid peptide dyad and then its conjugation with the fullerene subunit based on esterification and amidation reactions with protection-deprotection steps required. Two

different activating systems, DCC/DMAP and EDC/HOBt in dichloromethane were used to optimize these reactions. The DCC/DMAP-assisted esterification of *N*-protected GABA **36** with sterol **37** led smoothly to the ester **38** in very good yield (80%), while in the presence of EDC/HOBt no product was isolated.


The steroid peptide dyad **39** was coupled with Boc-Gly-OH<sup>43</sup> after a quantitative Boc-deprotection with TFA. This latter was isolated with an excellent yield (93%) and used for two different syntheses of steroidal hybrids. The reaction of **40** with Fp-GABA-OH led to fullerene-peptide-steroid hybrid **40** in a 63% yield and reaction with GABA afforded a steroid dipeptide dyad **41** presenting an elongation of the peptide chain (Scheme 9). Finally, triad **42** was isolated in a poor yield of 19% after Boc-removal and a subsequent coupling with a fullerene unit. The yield is lower than this obtained using a shorter peptide. The DCC/DMAP activating system seems to be somewhat more efficient for amidations including both Boc-Gly-OH and Fp-GABA-OH (reactions 3/4 and 4/5, respectively) than for esterification of Boc-GABA **36**.

This synthetic approach can be used to generate different steroid-fullerene derivatives with potential biological activity. High antioxidant activity of these new hybrids, twice and 13-fold better than fullerene C<sub>60</sub> and standard antioxidant agent vitamin C, respectively, was observed after an *in vitro* study using the Ferrous ion Oxidation-Xylenol orange (FOX) method.



Reagents : a- DCC/DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0°C to r.t., 24 h; b- TFA, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 2 h;  
c- Boc-Gly-OH, TEA, DCC/DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0°C to r.t., 24 h;  
d- Fp-GABA-OH, TEA, DCC/DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0°C to r.t., 24 h.

**Scheme 8.** Synthesis of steroid-fullerene hybrid **40**.




Reagents : b- TFA, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 2 h; c- Boc-Gly-OH, TEA, DCC/DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0°C to r.t., 24 h;  
 d- Fp-GABA-OH, TEA, DCC/DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0°C to r.t., 24 h.

### Scheme 9. Synthesis of steroid-fullerene hybrid **42**.

In 2017, Martin and coworkers<sup>44</sup> reported for the first time a controlled diastereoselective synthesis of *cis* and *trans* steroid–fulleropyrrolidines hybrids by reaction of *N*-metallated azomethine ylides [Cu(II) or Ag(I)] with the appropriate chiral ligand and C<sub>60</sub>.

To obtain the target steroid-fullerene hybrids, the authors first synthesized the imine **43** by reaction of the previously reported<sup>39</sup> 3-chloro-2-formyl-17-oxo-5 $\alpha$ -androstan-2-ene **26** and the glycine methyl ester hydrochloride using triethylamine as a base and dichloromethane as solvent at room temperature (see Scheme 10). This imine was isolated in a good yield (77%) as a yellow oil. The coupling of this latter with C<sub>60</sub> using anhydrous silver acetate along with the achiral ligand [dppe, 1,2-bis(diphenylphosphino)ethane] in toluene at room temperature led to a mixture of the two *cis*-diastereomers **44** and **45**. It is worth pointing out that the stabilization of the *N*-metallated azomethine ylide is provided by the allylic moiety of the steroid unit. The two products were separated by flash chromatography to give **44** in a yield of 32% and **45** in a yield of 25% (see Scheme 10). We can see that the stereoselectivity is modest due to poor chiral induction of the steroid moiety on the attack to one of the faces of the dipole in the fullerene derivative.






Reagents : a- Cl<sup>-</sup>, <sup>+</sup>H<sub>3</sub>N-CH<sub>2</sub>COOCH<sub>3</sub>, NEt<sub>3</sub>, DCM, r.t.; b- C<sub>60</sub>, AgOAc, dppe, toluene, r.t.

**Scheme 10.** Synthesis of steroid-fullerene hybrids **44** and **45**.


The same reaction was done with other catalytic systems to ascertain their stereocontrol in the 1,3-dipolar cycloaddition of azomethine ylides onto C<sub>60</sub> even in the presence of a chiral moiety, such as the imine **43**. Thus, the reaction of steroid iminoester **43** onto C<sub>60</sub> with the catalytic complex Cu(II)-Fesulphos at 0 °C led to *cis*-(2*S*,5*R*)-2-methoxycarbonyl-5-(3'*β*-acetoxy-17'-chloro-5'*α*-16'-androstene) pyrrolidino [3,4:1,2][60]fullerene **44** with an excellent diastereomeric induction (see Scheme 11). Using the catalytic system AgOAc/(*R,R*)-BPE at the same temperature, the *cis* diastereoisomer (2*R*,5*S*) (*cis*-2-methoxycarbonyl-5-(3'*β*-acetoxy-17'-chloro-5'*α*-16'-androstene)pyrrolidino[3,4:1,2]-[60]-fullerene **45** showing an opposite configuration in the pyrrolidine ring is obtained, also with excellent diastereoselectivity. For both catalysts, the counterion of the metal salt which is acetate reacts like a base and is probably located in the empty metal

coordination sphere, which is the origin of this good stereodifferentiation.<sup>45</sup> This diastereodivergent study was completed using bulky chiral ligand DTBM-Segphos<sup>46,47</sup> to obtain the *trans*-diastereomers. Thus, the use of the Cu(II)-(R)-DTBM-Segphos complex in the presence of triethylamine as the base at room temperature leads to the *trans*-diastereoisomer **46** with (2*R*, 5*R*) configuration. And, the same reaction carried out with the Cu(II)-(S)-DTBM-Segphos complex under the same conditions leads to the *trans*-diastereomer **47** with a (2*S*, 5*S*) configuration.


This is an efficient stereodivergent protocol to synthesize hybrid systems in a diastereoselective manner allowing access to a variety of optically active fullerene hybrids.




Reagents : a-Cu(AcO)<sub>2</sub>, FeSulphos, 0 °C, 2 h; b- AgOAc, BPE, 0 °C, 2 h; c- Cu(OTf)<sub>2</sub>,  
*R*-DTBM-Segphos, NEt<sub>3</sub>, 2 h, r.t.; d- Cu(OTf)<sub>2</sub>, *S*-DTBM-Segphos, NEt<sub>3</sub>, 2 h, r.t.



FeSulPhos



BPE




R = 2,3-*t*Bu-3-OMe-Ph  
 DTBM-Segphos

**Scheme 11.** Synthesis of steroid-fullerene hybrids **44-47**.

In 2018, the same authors<sup>48</sup> described the synthesis of new [60]fullerene-steroid hybrids by Bingel–Hirsch protocol of the corresponding steroid containing malonates with C<sub>60</sub>.

The synthesis started with the preparation of compounds **52**, **53**, and **54** from commercially available epiandrosterone **48**, in which functional groups in C3 and C17 positions were transformed. Thus, the steroid derivative **48** was treated with acetic anhydride in pyridine and led to the corresponding 3 $\beta$ -acetoxy-5 $\alpha$ -androstane-17-one **49** in a good yield. As expected, the reduction of compound **49** with sodium borohydride in methanol afforded with stereoselective control the 3 $\beta$ -acetoxy-5 $\alpha$ -androstane-17 $\beta$ -ol **50**. In the following step, 5 $\alpha$ -androstane-3 $\beta$ ,17 $\beta$ -diol **51** was isolated after basic hydrolysis of the previous compound in a similar yield as this reported.<sup>49,50</sup>

The sterol derivatives **48**, **50**, and **51** were transformed into the corresponding malonates **52-54** by reaction with the commercially available (ethoxycarbonyl)acetyl chloride (Scheme 12). The reaction was carried out in anhydrous dichloromethane and pyridine at 0°C and led to the derivatives **52**, **53**, and **54** in 80, 72, and 75% yields, respectively.




Reagents : a- acetic anhydride, pyridine, 5 h, r.t.; b- NaBH<sub>4</sub>, MeOH, r.t., 25 min;  
c- K<sub>2</sub>CO<sub>3</sub>, 5%, MeOH, r.t., 24 h; d- CH<sub>3</sub>CH<sub>2</sub>OCOCH<sub>2</sub>COCl, pyridine, DCM, 0 °C.

#### Scheme 12. Synthesis of steroid derivatives **52-54**.

The steroid-fullerene hybrids **52**, **53**, or **54** were synthesized using the Bingel–Hirsch conditions by reaction of C<sub>60</sub> and the malonyl steroids **52**, **53**, or **54**, with CBr<sub>4</sub> and DBU at room temperature (see Scheme 13). The cyclopropanation process was confirmed by the change of the color of the solution (purple to brown) leading to the [6,6] mono-adduct. In the case of compounds **55** and **56**, the reaction was finished in 2 h and furnished after purification by flash chromatography, compounds **55** and **56** in 68 and 58% yields, respectively, as stable

brown solids. While, the reaction between  $C_{60}$  and dimalonate **54** led to three hybrid systems **57**, **58**, and **59** in 42%, 12%, and 11% yields, respectively.



Reagents : a-  $C_{60}$ , DBU/ $CBr_4$ , toluene, r.t.


**Scheme 13.** Synthesis of steroid-fullerene hybrids **55-59**.

In 2020, Martin and coworkers<sup>51</sup> developed a synthetic strategy based on a multistep approach to synthesize novel fullerene-steroid hybrids.

The synthesis required the obtention of malonyl derivatives **61** and **62** to fix the [60]fullerene cage by a Bingel–Hirsch reaction (Scheme 14). Thus, dehydroepiandrosterone **60** (DHEA) was transformed into malonates **61** and **62** by reaction with commercially available (ethoxycarbonyl)acetyl chloride and malonyl chloride, respectively. These reactions were carried out in anhydrous dichloromethane (DCM) and pyridine at 0 °C. The purified compounds **61** and **62** were obtained with 82% and 78% yields, respectively. The Bingel–Hirsch protocol was used to synthesize the novel methano[60]fullerenes **63** and **64**, by reaction of either **61** or **62** with [60]fullerene in the presence of CBr<sub>4</sub> and DBU at room temperature. After 2 h and purification by flash chromatography, compounds **63** and **64** were isolated as stable brown solids in 74 and 51 % yields, respectively.

It is interesting to note that the DHEA moiety in the [60]fullerene systems **63**, and **64** increases the solubility in organic solvents, such as chloroform, dichloromethane, dimethylformamide, and dimethylsulfoxide. This fact might be useful since biological studies could be realized in some of these solvents. Indeed, in general, *in vitro* tests with the HIV-1 protease are performed in DMSO<sup>52</sup> due to the poor solubility of fullerene derivatives in water.

The TEM analysis showed that steroid-fullerene hybrids in water give nano-sized spherical vesicles with highly heterogeneous size populations. Moreover, DFT theoretical calculations revealed that hydrogen bonds play a major role in the geometry of these hybrid systems. And finally, these derivatives could have an application as HIV-1 protease inhibitors as suggested by molecular docking studies. All the characteristics of C<sub>60</sub>-steroid derivatives (including polarity, lipophilicity) constitute promising results to further explore the biomedical aspects of these molecular chimeras.



Reagents : a-  $\text{CH}_3\text{CH}_2\text{OCOCH}_2\text{COCl}$ , pyridine, DCM,  $0^\circ\text{C}$ ; b-  $\text{ClOCOCH}_2\text{COCl}$ , pyridine, DCM,  $0^\circ\text{C}$ ; c-  $\text{C}_{60}$ , DBU,  $\text{CBr}_4$ , toluene, r.t.


**Scheme 14.** Synthesis of steroid-fullerene hybrids **63** and **64**.

The same year, Martin and coworkers<sup>53</sup> also reported the synthesis of two new diastereomeric steroid [60]fullerene hybrids in a single 1,3-dipolar cycloaddition reaction.

The synthetic pathway is depicted in Scheme 15. A 1,3-dipolar cycloaddition reaction of steroidal derivatives with  $\text{C}_{60}$  via azomethine ylides generated *in situ* led to *N*-methyl-2-substituted pyrrolidino-[3,4:1,2][60]fullerenes possessing steroidal moieties. Thus, the reaction of the enantiopure formyl steroidal derivative (*8S,9S,10R,13S,14S,17R,20S*)-3-oxopregn-4-ene-20-carboxaldehyde, **65**,  $\text{C}_{60}$ , and sarcosine in toluene under argon atmosphere led to the corresponding fullerene cycloadducts **66** and **67** after 5 h of reflux (Scheme 15).

The formation of the five-membered ring occurred with the formation of a new stereogenic center on the C-2 of the pyrrolidine ring by a stereospecific *syn* process. Since the configuration of the stereogenic centers of the steroid always remains the same, the reaction led to a mixture of diastereoisomers of derivatives **66** and **67**, which were separated by flash chromatography. Thus, products **66** and **67** were isolated as stable brown solids with yields of 68% and 13%, respectively. The diastereoselectivity of the reaction could be explained by a preferential electrophilic attack of C<sub>60</sub> on the *Re* face of the 1,3-dipole. As a result, the steric interactions due to the presence of the methyl group at C-20 are at the origin of the attack on the *Si* face. Thus, the 5:1 ratio (*Re:Si*) observed is explained by an attack on the [60]fullerene on the *Re* face of the 1,3-dipole due to lower steric hindrance.

Here too, it is worth noting the increase in the solubility of derivatives **66** and **67** in organic solvents. This fact is very interesting to consider possible biological studies on materials. Additionally, these hybrids can potentially be used as HIV-1 protease inhibitors. These are very encouraging results that could be the source of many applications (biology, materials, etc.).



Reagents : a- C<sub>60</sub>, N-methylglycine, toluene, reflux, under argon.

### Scheme 15. Synthesis of steroid-fullerene hybrids **66** and **67**.


Recently, the same authors<sup>54</sup> reported the synthesis and characterization of a fullerene-steroid hybrid that contains H<sub>2</sub>@C<sub>60</sub> and a dehydroepiandrosterone moiety synthesized by a cyclopropanation reaction.

The authors observed that the encapsulation of a hydrogen molecule does not in any way modify the reactivity or the stereoselectivity of the C<sub>60</sub> hollow fullerene.<sup>24</sup> The synthesis is depicted in Scheme 16. The new endohedral steroid-fullerene hybrid **69** was prepared by applying the Bingel-Hirsch protocol between 3β-ethyl malonate-5-androsten-17-one **52**<sup>51</sup> and H<sub>2</sub>@C<sub>60</sub>. The H<sub>2</sub>@[60]fullerene, compound **52**, CBr<sub>4</sub>, and DBU mixture produced at room temperature very quickly leads to a change in the color of the solution from purple



to brown, identical to that observed when the reaction is carried out using unmodified  $C_{60}$ <sup>51</sup> and indicative of the success of the reaction. Thus, the [6,6]-closed mono-adduct **69** was isolated in a good yield (76%) as a stable brown solid. The endohedral hybrid is obtained with yields and reaction times similar to those obtained during hollow  $C_{60}$  fullerene reactions with steroids.<sup>51</sup>

It is therefore interesting to note that the presence of the  $H_2$  molecule inside the cavity of the fullerene does not affect the reactivity of the hollow fullerene. Furthermore, the authors have shown that in the hybrid system **69**, the hydrogen molecule does not present a clear perpendicular disposition to one of the hexagonal rings of the fullerene cage.



**Scheme 16.** Synthesis of steroid-fullerene hybrid **69**.

Theoretical studies were considered on the new endohedral steroid-fullerene hybrid **69** to evaluate its biological potential. It was thus observed that it would have higher antiviral properties, in particular against Covid-19, than its hollow counterparts. Of course, these preliminary and encouraging results will have to be verified by future *in vitro* and *in vivo* tests.

### 3. Conclusions

The present review offers up-to-date literature on the syntheses of steroid-fullerene hybrids reported during the last years. The coupling of two or more natural products to make hybrids makes it possible to obtain new types of compounds with various structures, at the origin of improved properties compared to the starting molecules or at the origin of new properties. The biological aspect and all the properties of these molecules are still not well-known. But it is expected that the synthesis of fullerene derivatives will continue in the years to come as well as the still current interest in the chemistry of steroids and their derivatives given the applications (biological or in the chemistry of materials) inherent to this family of compounds.

### 4. Acknowledgements

This work has been financially supported by the CNRS and the Ministère de l'Enseignement Supérieur et de la Recherche.

## 5. References

1. Zeelen, J. F. Medicinal chemistry of steroids; Elsevier: Amsterdam, Netherlands, **1990**.
2. Trager, L. F. Steroidhormone; Springer: Berlin, **1977**.
3. Biellmann, J. F. *Chem. Rev.* **2003**, *103*, 2019.  
<http://doi.org/10.1021/cr020071b>
4. Nising, C. F.; Bräse, S. *Angew. Chem. Int. Ed.* **2008**, *47*, 9389.  
<https://doi.org/10.1002/anie.200803720>
5. Hanson, J. R. *Nat. Prod. Reports* **2010**, *27*, 887.  
<https://doi.org/10.1039/C001262A>
6. Tzirakis, M. D.; Orfanopoulos, M. *Chem. Rev.* **2013**, *113*, 5262.  
<https://doi.org/10.1021/ja808658b>
7. Lu, X.; Feng, L.; Akasaka, T.; Nagase, S. *Chem. Soc. Rev.* **2012**, *41*, 7723.  
<https://doi.org/10.1039/C2CS35214A>
8. Das, S.; Presselt, M. *J. Mater. Chem. C* **2019**, *7*, 6194.  
<https://doi.org/10.1039/C9TC00889F>
9. Kang, S.; Zhang, J.; Sang, L.; Shrestha, L. K.; Zhang, Z.; Lu, P.; Li, F.; Li, M.; Ariga, K. *ACS Appl. Mater. Interfaces* **2016**, *8*, 24295.  
<https://doi.org/10.1021/acsami.6b06221>
10. Badamshina, E.; Estrin, Y.; Gafurova, M. *J. Mater. Chem. A* **2013**, *1*, 6509.  
<https://doi.org/10.1039/C3TA10204A>
11. Stroyuk, O.; Raevskaya, A.; Gaponik, N. *Chem. Soc. Rev.* **2018**, *47*, 5354.  
<https://doi.org/10.1039/C8CS00029H>
12. Martynov, I. V.; Akkuratov, A. V.; Luchkin, S. Y.; Tsarev, S. A.; Babenko, S. D.; Petrov, V. G.; Stevenson, K. J.; Troshin, P. A. *ACS Appl. Mater. Interfaces* **2019**, *11*, 21741.  
<https://doi.org/10.1021/acsami.9b01729>
13. Zhu, S.-E.; Li, F.; Wang, G.-W. *Chem. Soc. Rev.* **2013**, *42*, 7535.  
<https://doi.org/10.1039/C3CS35494F>
14. Badamshina, E.; Gafurova, M. *J. Mater. Chem.* **2012**, *22*, 9427.  
<https://doi.org/10.1039/C2JM15472B>
15. Cao, Z.; Zhao, W.; Liu, Q.; Liang, A.; Zhang, J. *Adv. Mater. Interfaces* **2018**, *5*, 1701303.  
<https://doi.org/10.1002/admi.201701303>
16. Sun, J.; Du, S. *RSC Adv.* **2019**, *9*, 40642.  
<https://doi.org/10.1039/C9RA05679C>
17. Zhang, R.; Xiong, L.; Pu, J.; Lu, Z.; Zhang, G.; He, Z. *Adv. Mater. Interfaces* **2019**, *6*, 1901386.  
<https://doi.org/10.1002/admi.201901386>
18. Wu, K.; Qiang, L.; Gong, Z.; Zhao, G.; Gao, K.; Zhang, B.; Zhang, J. *Surf. Interface Anal.* **2015**, *47*, 903.  
<https://doi.org/10.1002/sia.5793>
19. Uchikawa, S.; Kawasaki, A.; Hoshino, N.; Takeda, T.; Noro, S.I.; Takahashi, K.; Nakamura, T.; Sato, N.; Kokubo, K.; Sakurai, H.; Akutagawa, T. *J. Phys. Chem. C* **2019**, *123*, 23545.

- <https://doi.org/10.1021/acs.jpcc.9b06951>
20. Velzeboer, I.; Kwadijk, C. J. A. F.; Koelmans, A. A. *Environ. Sci. Technol.* **2014**, *48*, 4869.  
<https://doi.org/10.1021/es405721v>
21. Avanası, R.; Jackson, W. A.; Sherwin, B.; Mudge, J. F.; Anderson, T. A. *Environ. Sci. Technol.* **2014**, *48*, 2792.  
<https://doi.org/10.1021/es405306w>
22. Zhang, M.; Tao, S.; Wang, X. *Environ. Sci.: Nano* **2020**, *7*, 2486.  
<https://doi.org/10.1039/DOEN00515K>
23. Nierengarten, I.; Nierengarten, J.-F. *Chem. Asian J.* **2014**, *9*, 1436.  
<https://doi.org/10.1002/asia.201400133>
24. Hashimoto, A.; Takamura-Enya, T.; Oda, Y. *Photochem. Photobiol.* **2019**, *95*, 1403.  
<https://doi.org/10.1111/php.13138>
25. Bianco, A.; Da Ros, T. Biological Applications of Fullerenes. Fullerenes: Principles and Applications; The Royal Society of Chemistry: London, UK, **2011**, *2*, 507-545.  
<https://doi.org/10.1039/9781849732956-00507>
26. Plehn, T.; Megow, J.; May, V. *Phys. Chem. Chem. Phys.* **2014**, *16*, 12949.  
<https://doi.org/10.1039/C4CP01081G>
27. Chen, T.; Zou, H.; Wu, X.; Chen, Y.; Situ, B.; Zheng, L.; Yang, G. *ACS Biomater. Sci. Eng.* **2019**, *5*, 3079.  
<https://doi.org/10.1021/acsbiomaterials.9b00372>
28. Zhai, Y.; Zhu, Z.; Dong, S. *ChemCatChem* **2015**, *7*, 2806.  
<https://doi.org/10.1002/cctc.201500323>
29. Shah, S.; Tiwari, N.; Kumar, Y.; Jha, S. N.; Auroux, A.; Pandey, J. K.; Chowdhury, B. *ChemistrySelect* **2017**, *2*, 5640.  
<https://doi.org/10.1002/slct.201700203>
30. Gopiraman, M.; Saravanamoorthy, S.; Ullah, S.; Ilangovan, A.; Kim, I. S.; Chung, I. M. *RSC Adv.* **2020**, *10*, 2545.  
<https://doi.org/10.1039/C9RA09244G>
31. Beck, M. T.; Mandi, G.; Keki, S. *Proc. Electrochem. Soc.* **1995**, 95.  
<https://doi.org/10.1080/1536383X.2010.481063>
32. An, Y. Z.; Ellis, G. A.; Viado, A. L.; Rubin, Y. *J. Org. Chem.* **1995**, *60*, 6353.  
<https://doi.org/10.1021/jo00125a022>
33. Bingel, C. *Chem. Ber.* **1957**, *8*, 126.  
<https://doi.org/10.1002/cber.19931260829>
34. Fong, R.; Schuster, D. I.; Wilson, S. R. *Org. Lett.* **1999**, *1*, 729.  
<https://doi.org/10.1021/ol990722z>
35. Maggini, M.; Scorrano, G.; Prato, M. *J. Am. Chem. Soc.* **1993**, *115*, 9798.  
<https://doi.org/10.1021/ja00074a056>
36. Li, L. S.; Hu, Y. J.; Wu, Y.; Wu, Y. L.; Yang, F. *J. Chem. Soc., Perkin Trans. 1*, **2001**, 617.  
<https://doi.org/10.1039/B007498P>
37. Coro, J.; Rodríguez, H.; Rivera, D. G.; Suárez, M.; Molero, D.; Herranz, M. Á.; Martínez-Álvarez, R.; Filippone, S.; Martín, N. *Eur. J. Org. Chem.* **2009**, 4810.  
<https://doi.org/10.1002/ejoc.200900583>
38. Kim, D. S.; Baek, N.; Oh, S. R.; Jung, K. Y.; Lee, I. S.; Kim, J. H.; Lee, H. *Arch. Pharmacol Res.* **1997**, *20*, 201.

39. Ruiz, A. ; Coro, J.; Almagro, L.; Ruiz, J. A. ; Molero, D.; Maroto, E. E.; Filippone, S.; Herranz, M. Á.; Martínez-Álvarez, R.; Sancho-García, J. C.; Di Meo, F.; Suárez, M.; Martín, N. *J. Org. Chem.* **2013**, *78*, 2819.  
<https://doi.org/10.1021/jo302528t>
40. Raeside, J. I.; Renaud, R. L.; Marshall, D. E. *J. Steroid Biochem. Mol. Biol.* **1992**, *42*, 113.  
[https://doi.org/10.1016/0960-0760\(92\)90017-d](https://doi.org/10.1016/0960-0760(92)90017-d)
41. Ruiz, A. ; Coro, J.; Almagro, L.; Ruiz, J. A. ; Molero, D.; Maroto, E. E.; Filippone, S.; Herranz, M. Á.; Martínez-Álvarez, R.; Sancho-García, J. C.; Di Meo, F.; Suárez, M.; Martín, N. *J. Org. Chem.* **2014**, *79*, 3473.  
<https://doi.org/10.1021/jo5005907>
42. Bjelakovic, M. S.; Kop, T. J.; Vlajic, M.; ĐorCevic, J.; Milic, D. R. *Tetrahedron* **2014**, *70*, 8564.  
<https://doi.org/10.1016/j.tet.2014.09.070>
43. Schwarc, S.; Csuk, R. *Bioorg. Med. Chem.* **2010**, *18*, 7458.  
<http://dx.doi.org/10.1016/j.bmc.2010.08.054>
44. Suárez, M.; Ruiz, A.; Almagro, L.; Coro, J.; Maroto, E. E.; Filippone, S.; Molero, D.; Martínez-Álvarez, R.; Martín, N. *J. Org. Chem.* **2017**, *82*, 4654.  
<http://dx.doi.org/10.1021/acs.joc.7b00286>
45. Filippone, S.; Maroto, E. E.; Martín-Domenech, A.; Suárez, M.; Martín, N. *Nat. Chem.* **2009**, *1*, 578.  
<http://dx.doi.org/10.1038/nchem.361>
46. Maroto, E. E.; Filippone, S.; Martín-Domenech, A.; Suárez, M.; Martín, N. *J. Am. Chem. Soc.* **2012**, *134*, 12936.  
<https://doi.org/10.1021/ja306105b>
47. Maroto, E. E.; Filippone, S.; Suárez, M.; Martínez-Álvarez, R.; de Cózar, A.; Cossío, F. P.; Martín, N. *J. Am. Chem. Soc.* **2014**, *136*, 705.  
<https://doi.org/10.1021/ja410408c>
48. Ruiz, A. ; Coro, J.; Almagro, L.; Ruiz, J. A. ; Molero, D.; Maroto, E. E.; Filippone, S.; Herranz, M. Á.; Martínez-Álvarez, R.; Sancho-García, J. C.; Di Meo, F.; Suárez, M.; Martín, N. *Eur. J. Org. Chem.* **2018**, *33*, 4512.  
<http://dx.doi.org/10.1002/ejoc.201800622>
49. Reyes-Moreno, M.; Fuente-Hernández, A.; Ruiz-García, J. A.; Álvarez-Ginarte, Y. M.; Vélez-Castro, H.; Fernández-Villalobo, A.; Montiel-Smith, S.; Meza-Reyes, S.; Sandoval-Ramírez, J. *J. Mex. Chem. Soc.* **2007**, *51*, 232.  
<https://doi.org/10.1021/ja074536x>
50. Reyes, M.; Ruiz, J. A.; Ibarra, Y.; Fuente, A.; Vélez, H.; Hernández, I.; Martínez, I.; Rodeiro, I.; Sandoval, J.; Meza, S.; Montiel, S. *Eur. J. Med. Chem.* **2009**, *44*, 4567.  
<https://doi.org/10.1016/j.ejmech.2008.03.003>
51. Ruiz, A.; Lemos, R.; Makowski, K.; Rodríguez, H.; Ortiz, O.; Cáceres, W.; Ángeles Herranz, M.; Molero, D.; Martínez-Álvarez, R.; Suárez, M.; Martín, N. *Eur. J. Org. Chem.* **2020**, *37*, 5926.  
<https://doi.org/10.1002/ejoc.202000989>
52. Castro, E.; Martinez, Z. S.; Seong, C. S.; Cabrera-Espinoza, A.; Ruiz, M. A.; García, H.; Valdez, F.; Llano, M.; Echegoyen, L. *J. Med. Chem.* **2016**, *59*, 10963.  
<https://doi.org/10.1021/acs.jmedchem.6b00994>
53. Alonso, D.; Hernández-Castillo, D.; Almagro, L.; González-Alemán, R.; Molero, D.; Ángeles Herranz, M;

Medina-Páez, E.; Coro, J.; Martínez-Álvarez, R.; Suárez, M.; Martín, N. *J. Org. Chem.* **2020**, *85*, 2426.

<https://dx.doi.org/10.1021/acs.joc.9b03121>

54. Suárez, M.; Makowski, K.; Lemos, R.; Almagro, L.; Rodríguez, H.; Herranz, M. A.; Molero, D.; Ortiz, O.; Maroto, E.; Albericio, F.; Murata, Y.; Martín N. *ChemPlusChem* **2021**, *86*, 972.

<https://doi.org/10.1002/cplu.202000770>

## Authors' Biographies



**Malika Ibrahim-Ouali** carried out her Ph.D. under the supervision of Professor Gramain in Clermont-Ferrand (France) in 1996. The work was focused on the synthesis of alkaloids. She was a postdoctoral fellow with Prof. Knochel (Humboldt fellowship) in 1996 in Germany where she got her first training in organometallic chemistry. In 1997, she joined Professor H. P Husson's group at the ICSN (Paris) as a postdoctoral researcher. Since 1998, she is currently an Associate Professor at Aix-Marseille University, and her field of interest remains the total synthesis of natural compounds.



**Frédéric Dumur** received his Ph.D. in chemistry in 2002 from the University of Angers (France) under the supervision of Professor Pietrick Hudhomme. After Post-Doctoral studies at the University of Groningen (The Netherlands), Reims Champagne-Ardennes (France) and Versailles Saint-Quentin-en-Yvelines (France), he joined the Faculty of Sciences at Aix-Marseille University in 2008, where he is currently working as an Associate Professor. His research interests include the synthesis of phosphorescent dopants for OLEDs and photoinitiators of polymerization. He co-authored about 300 publications and 5 book chapters.

**DEFINITIVE COPY. DO NOT DELETE THIS MESSAGE.**

**Please ensure that all changes are made in this copy.**

All changes to this manuscript must be made on this copy, whether it is then uploaded into the Arkivoc manuscript database or sent to the Scientific Editor.

The notifications in red here will be **removed by the Publishing Editor** at the Publication stage.

